Home > Inhibitors & Agonists > Wnt/Notch/Hedgehog > Beta-catenin
Cat. No. Product name CAS No.
DCL-046 Triptolide,14-deoxy-14-oxo

>98%,Standard References

38647-11-9
DCS-054 Carnosic acid

>98%,Standard References

3650-09-7
DC10976 E-7386

E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.

1799824-08-0
DC7414 FH535 Featured

FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.

108409-83-2
DC3130 ICG-001 Featured

ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro

780757-88-2
DC10680 iCRT3 Featured

iCRT3 is an inhibitor of both Wnt and β-catenin-responsive transcription.

901751-47-1
DC9952 IQ-1 Featured

IQ-1 has many functions such as decreasing Wnt-stimulated phosphorylation, maintaining the pluripotency of murine ESCs, preventing PP2A/Nkd interaction and so on.

331001-62-8
DC10556 KY1220 Featured

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells.

292168-79-7
DC9880 KYA1797K Featured

KYA1797K is a highly potent and selective Wnt/β-catenin inhibitor with IC50 of 0.75 µM (TOPflash assay).

1956356-56-1
DC12384 LF3 Featured

LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 with an IC50 less than 2 μM.

664969-54-4
DC10409 PNU-74654

PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell.

113906-27-7
DC10888 SKL2001 Featured

SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity.

909089-13-0
DC10472 Toxoflavin (PKF118-310) Featured

Toxoflavin is an inhibitor of survivin expression and antagonist of Tcf4/b-catenin signaling

84-82-2
DC28730 N-Desmethylnefopam

N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.

46868-19-3
DC29001 CWP232228 Featured

CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs).

1144044-02-9
DC40956 β-catenin-IN-2

β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.

1458664-10-2
DC46190 PRI-724 Featured

PRI-724 (C-82 prodrug, ICG-001 analog) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP.

1422253-38-0
DC46310 Nefopam D3 hydrochloride

Nefopam D3 hydrochloride is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.

1346603-30-2
DC46397 ZW4864 free base

ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM.

2632259-92-6
DC46398 ZW4864

ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM.

2632259-93-7
DC70375 E722-2648

E722-2648 (Compound C-1) is a novel specific and competitive small molecule β-catenin/BCL9 interaction inhibitor with ITC KD of 1.05 uM and IC50 of 9 uM, blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.E722-2648 (Compound C-1) inhibited β-catenin/BCL9 complexes at concentrations as low as 1 uM in BCL9-dependent CRC cell lines, Colo320 and HCT116.E722-2648 (Compound C-1) inhibited the expression of bona fide downstream Wnt/β-catenin target genes, AXIN2 and CD44, in the β-catenin/BCL9-dependent CRC cell lines.E722-2648 (Compound C-1) disrupted cholesterol homeostasis via increased cholesterol esterification and lipid droplet accumulation.E722-2648 (Compound C-1) demonstrated antitumorigenic activity in CRC cell lines and xenograft mouse models.

931963-55-2
DC70427 GB1874

GB1874 is an inhibitor of the Wnt pathway that targets the β-catenin-TCF4 interaction.GB1874 affected the proliferation and stemness of Wnt-addicted colorectal cancer (CRC) cells in vitro.GB1874 inhibited the growth of CRC tumor xenografts in vivo.

1011440-46-2
Page 1 / Total 2 FirstPrevNextLastGoto